Moderna and Merck announced on Oct. 22 that a personalized mRNA cancer vaccine reduced the risk of melanoma recurrence or death by 42% over two years when paired with Merck's immunotherapy Keytruda, a result that could reshape how Southeast Asian health systems budget for oncology.
The findings, reported by Yahoo News, come from a Phase 3 trial of more than 1,130 patients with Stage 2B to Stage 4 melanoma whose tumors had been surgically removed, and will be presented at the European Society of Medical Oncology meeting in Madrid on Oct. 24.
How the intismeran and Keytruda combination works
The vaccine, called intismeran autogene, is custom-built for each patient after genetic sequencing of their tumor. It trains immune cells to recognize 34 specific proteins found on tumor cells, using mRNA encased in a lipid particle, the same delivery platform as Moderna's COVID vaccine.
Patients received intismeran once every three weeks for up to nine doses, alongside Keytruda every six weeks for up to nine cycles, over roughly a year. Keytruda, a checkpoint inhibitor, removes the brakes that stop immune cells from attacking tumors because they originate from normal self cells.
The pairing matters commercially as well as clinically. As CNBC reported, Moderna shares fell after the data leaked, despite the positive headline number, a reminder that markets price in expectations as much as outcomes.
Why the Phase 3 results surprised researchers
The 42% figure closely replicates earlier Phase 2 data, which showed a 49% reduction in the risk of cancer returning or death over one year, and a 59% lower risk of the cancer spreading to other sites compared with the checkpoint inhibitor alone.
“I was surprised by the fact that the results replicated the Phase 2 [study] so closely,” said Dr. David Berman, chief development officer at Moderna.
“This Phase 3 [study] included a much broader population, so the hypothesis was that the treatment effect would be harder to see. There was a lot of suspicion going in that these results would not be as good as those in the Phase 2. But the fact that they reproduced almost exactly what we saw initially in the Phase 2 blew my mind.”
The companies report that the treatment effect appears to begin around six months into therapy. Berman attributes the lag to the time the immune system needs to become fully activated, including T cells learning to detect tumors.
What the data explain about checkpoint inhibitors
Only about 30% of cancer patients respond to checkpoint inhibitors, one of oncology's most powerful recent tools. Berman says the new data suggest why: in many patients, the immune system has never been educated to recognize the cancer in the first place.
“This shows us that in a significant percentage of patients, the checkpoint inhibitors are not doing anything because the immune system hasn't even been educated to recognize the cancer cells,” he said. “That's where we now need to focus, on how to better educate the immune system.”
Data on overall survival for patients on the combination therapy is not yet available.
Can personalized cancer vaccines scale?
Personalized medicine has long struggled with cost and production timelines. Berman argues the mRNA platform changes that equation. Scientists at Moderna can build a customized vaccine from a patient's tumor within weeks, and the manufacturing process is purely enzymatic, requiring no cell cultures.
“We have scaled down the technical footprint and have plans to scale up [the program] to look at different tumors,” he said.
Moderna and Merck are testing the intismeran and Keytruda pairing in nine other studies covering cancers including pancreatic and gastric tumors, along with three late-stage trials in non-small cell lung cancer. An early study of intismeran alone in lung cancer is also underway.
Implications for Southeast Asia's healthcare and biotech sectors
For Singapore, which has positioned itself as a regional hub for precision medicine and clinical research, the trial strengthens the case for mRNA manufacturing capability on the island. The city-state's biomedical cluster, anchored by agencies such as EDB and A*STAR, has spent the past decade building exactly the kind of enzymatic, cell-free production infrastructure this vaccine class requires.
Across ASEAN, melanoma incidence is lower than in Western markets, but the trial's real significance lies in the platform. If mRNA vaccines work against tumor antigens in melanoma, the same approach could extend to lung, gastric and pancreatic cancers, all of which carry heavy burdens in the region.
Cost remains the open question for regional health systems. Bespoke vaccines priced like boutique therapies would strain even Singapore's financing model, let alone neighboring markets with thinner insurance penetration. Berman's claim of scalability is encouraging, but payers will want manufacturing cost data before committing.
Regulators will also watch closely. Singapore's Health Sciences Authority has been among the faster agencies in Asia to adapt frameworks for novel modalities, and the intismeran file will be an early test of how quickly personalized mRNA vaccines can move from trial data to market access in this part of the world.
FAQ
What is intismeran autogene?
It is a personalized mRNA cancer vaccine developed jointly by Moderna and Merck. Each dose is custom-made after sequencing a patient's tumor, encoding 34 tumor-specific proteins to train the immune system to attack the cancer.
How effective was the vaccine in the Phase 3 trial?
The combination of intismeran and Keytruda reduced the risk of melanoma recurrence or death by 42% over two years compared with Keytruda alone, according to results announced on Oct. 22.
When will the vaccine be available?
No date has been set. Overall survival data is not yet available, and the companies are still running trials in lung, pancreatic and gastric cancers. Regulatory filings would follow full data review.